Unknown

Dataset Information

0

Ranitidine Inhibition of Breast Tumor Growth Is B Cell Dependent and Associated With an Enhanced Antitumor Antibody Response.


ABSTRACT: Background:The histamine receptor 2 antagonist ranitidine is a commonly used, non-prescription, medication. It limits the development, growth, and metastasis of breast cancers in mouse models of disease. In this study, we examined the role of B cells in this response, the impact of ranitidine on the development of antitumor antibodies and subpopulations of natural killer cells using murine breast cancer models. Methods:Peripheral blood granulocyte populations were assessed in both E0771-GFP and 4T1 orthotopic tumor-bearing mice by evaluation of stained blood smears. Antibody responses were assessed both in terms of the levels of anti-GFP antibodies detected by enzyme-linked immunosorbent assay and also by antibody binding to the surface of tumor cells evaluated by flow cytometry. B cell and NK cell populations were examined in the draining lymph nodes and spleens of tumor-bearing animals, by flow cytometry with and without ranitidine treatment. Results:Oral ranitidine treatment was not associated with changes in peripheral blood granulocyte populations in tumor-bearing mice. However, ranitidine treatment was associated with the development of enhanced antitumor antibody responses. This was not limited to the tumor setting since ranitidine-treated mice immunized with ovalbumin also demonstrated increased IgG antibody responses. Analysis of B cell populations indicated that while B1 cell populations remained unchanged there was a significant decrease in B2 cells in the tumor-draining inguinal lymph nodes. Notably, ranitidine did not significantly inhibit primary tumor growth in B cell-deficient animals. Examination of NK cell populations revealed a significant decrease in the proportion of intermediately functionally mature NK cells populations (CD27+CD11b-) in ranitidine-treated tumor-bearing mice compared with untreated tumor-bearing controls. Conclusion:These data demonstrate an important role for B cells in the enhanced antitumor immune response that occurs in response to ranitidine treatment. Our findings are consistent with a model, whereby ranitidine reduces tumor-associated immune suppression allowing for the development of more effective antitumor responses mediated by B cells which may include the participation of NK cells. These data underline the importance of considering widely used histamine receptor antagonists as modulators of antitumor immunity to breast cancer.

SUBMITTER: Rogers D 

PROVIDER: S-EPMC6104125 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

Ranitidine Inhibition of Breast Tumor Growth Is B Cell Dependent and Associated With an Enhanced Antitumor Antibody Response.

Rogers Dakota D   Vila-Leahey Ava A   Pessôa Ana Clara AC   Oldford Sharon S   Marignani Paola A PA   Marshall Jean S JS  

Frontiers in immunology 20180815


<h4>Background</h4>The histamine receptor 2 antagonist ranitidine is a commonly used, non-prescription, medication. It limits the development, growth, and metastasis of breast cancers in mouse models of disease. In this study, we examined the role of B cells in this response, the impact of ranitidine on the development of antitumor antibodies and subpopulations of natural killer cells using murine breast cancer models.<h4>Methods</h4>Peripheral blood granulocyte populations were assessed in both  ...[more]

Similar Datasets

| S-EPMC10729150 | biostudies-literature
2013-09-30 | E-GEOD-42050 | biostudies-arrayexpress
| S-EPMC4939550 | biostudies-literature
| S-EPMC5006904 | biostudies-literature
| S-EPMC8124719 | biostudies-literature
| S-EPMC2824381 | biostudies-literature
| S-EPMC6584221 | biostudies-literature
| S-EPMC10491708 | biostudies-literature
| S-EPMC9867837 | biostudies-literature
| S-EPMC5479746 | biostudies-literature